• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Pegvisomant interference in GH assays results in underestimation of GH levels.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    74702.pdf
    Size:
    118.0Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Paisley, Angela N
    Hayden, K
    Ellis, A
    Anderson, John
    Wieringa, Gilbert E
    Trainer, Peter J
    Affiliation
    Department of Endocrinology, Christie NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK.
    Issue Date
    2007-03
    
    Metadata
    Show full item record
    Abstract
    INTRODUCTION: Pegvisomant use in acromegaly negates the use of GH levels to monitor disease activity. To achieve antagonism, plasma concentrations must be approximately 1000-fold greater than GH which with the high homology between the peptides makes GH measurement a challenge when pegvisomant is present. OBJECTIVE: We investigated the effect of pegvisomant on GH measured using commercially available assays. METHODS: Pooled serum samples with GH concentrations <0.38, 3.85 and 7.69 microg/l were spiked with increasing pegvisomant concentrations (9000-494 000 microg/l). Samples were analysed by the Nichols Advantage, DPC Immulite 2000, Diasorin IRMA, Beckman Access Dxl, Tosoh AIA and Wallac Delfia assays. RESULTS: With baseline GH <0.38 microg/l measured levels were <0.38 in all assays except Nichols, Diasorin and Beckman where GH peaked at 1.5, 9.6 and 17.7 micarog/l respectively at low pegvisomant concentrations, falling thereafter. With the other two samples, measured GH levels progressively fell with increasing pegvisomant concentrations, except the Beckman assay where an increase (30.8 microg/l) was seen at a pegvisomant concentration of 9000 microg/l; and Diasorin and Tosoh where smaller increases were seen at lower pegvisomant concentrations, levels gradually falling thereafter. CONCLUSION: The presence of pegvisomant resulted in artefactually low measured GH in most assays. We speculate this fall is due to assay antibody-binding pegvisomant, reducing the amount of available antibody to bind actual GH thereby producing less sandwich formation: the 'high-dose hook' effect. In most assays, this effect is modest and results in lower GH, but the level of interference makes them unsuitable for studies on the influence of pegvisomant on GH neuroregulation.
    Citation
    Pegvisomant interference in GH assays results in underestimation of GH levels. 2007, 156 (3):315-9 Eur. J. Endocrinol.
    Journal
    European Journal of Endocrinology
    URI
    http://hdl.handle.net/10541/70196
    DOI
    10.1530/eje.1.02341
    PubMed ID
    17322491
    Type
    Article
    Language
    en
    ISSN
    0804-4643
    ae974a485f413a2113503eed53cd6c53
    10.1530/eje.1.02341
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Automated 22-kD growth hormone-specific assay without interference from Pegvisomant.
    • Authors: Manolopoulou J, Alami Y, Petersenn S, Schopohl J, Wu Z, Strasburger CJ, Bidlingmaier M
    • Issue date: 2012 Oct
    • Concomitant, specific determination of growth hormone and pegvisomant in human serum.
    • Authors: Ørskov H, Frystyk J, Nielsen C, Hansen AT, Weeke J, Jørgensen JO
    • Issue date: 2007 Oct
    • Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
    • Authors: Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z, Strasburger CJ
    • Issue date: 2001 Jul
    • Detecting and solving the interference of pregnancy serum, in a GH immunometric assay.
    • Authors: Dias ML, Vieira JG, Abucham J
    • Issue date: 2013 Feb-Apr
    • Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
    • Authors: Freda PU, Post KD, Powell JS, Wardlaw SL
    • Issue date: 1998 Nov
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.